PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Haleon reports double-digit revenue growth

Tue, 20th Sep 2022 07:51

(Alliance News) - Stocks in London are set to open higher on Tuesday, as markets in London return to action following a bank holiday for the state funeral of Queen Elizabeth II.

Markets this week will be focused on major central bank decision, with the US Federal Reserve scheduled for Wednesday and the Bank of England on Thursday, among others.

In China on Tuesday, the nation's central bank left its benchmark lending rate unchanged, in line with market expectations.

The People's Bank of China held its one-year loan prime rate - which serves as a benchmark for corporate loans - at 3.65%, while the five-year rate remained at 4.3%.

Australia's central bank on Tuesday said it expects to implement more interest rate hikes, but sees the case for a slower pace of increase as it seeks to keep the economy on "an even keel" while fighting inflation, minutes from its latest meeting showed.

The Reserve Bank of Australia increased the cash rate target earlier in September by half a percentage point to stand at 2.35% from 1.85% previously. This was the central bank's fourth consecutive 50 basis point rate hike since June.

Headlining UK company updates early Tuesday, GSK-spinoff Haleon reported double-digit revenue growth in the first half of the year.

Here is what you need to know ahead of the London market open:

----------

MARKETS

----------

FTSE 100: called up 0.6% at 7,281.40

----------

Hang Seng: up 1.1% at 18,761.66

Nikkei 225: closed up 0.4% at 27,688.42

S&P/ASX 200: closed up 1.3% at 6,806.40

----------

DJIA: closed up 197.26 points, or 0.6%, at 31,019.68

S&P 500: closed up 26.56 points, or 0.7%, at 3,899.89

Nasdaq Composite: closed up 86.62 points, or 0.8%, at 11,535.02

----------

EUR: up at USD1.0035 (USD1.0025)

GBP: up at USD1.1444 (USD1.1431)

USD: up at JPY143.30 (JPY142.93)

Gold: down at USD1,673.68 per ounce (USD1,677.01)

Oil (Brent): flat at USD92.29 a barrel (USD92.24)

(changes since previous London equities close)

----------

ECONOMICS

----------

Tuesday's key economic events still to come:

1000 CEST EU balance of payments

0830 EDT US housing starts

0855 EDT US Johnson Redbook retail sales index

1630 EDT US API Weekly statistical bulletin

----------

Producer price inflation in Germany accelerated to another record high in August, data from the Federal Statistics Office showed. In August, the producer price index increased by 45.8% compared to the same month a year prior, compared to a 37.2% increase in July, and well above consensus market expectations of a 37.5% hike, according to FXStreet. On a monthly basis, the producer price index rose by 7.9% in August from July, also a record and compared to a 5.3% rise in July from June. The acceleration was due to energy prices, which more than doubled as a result of strong rises electricity and natural gas prices.

----------

UK Prime Minister Liz Truss is committing to spend at least GBP2.3 billion next year on military aid to help Ukraine fend off Vladimir Putin's invasion. Truss pledged the UK will match or exceed the record support given to Volodymyr Zelensky's "inspirational" troops. Truss announced the support as she prepared to fly to New York, where she will use a United Nations summit in the US to rally support in helping Ukraine fight Russia. She will also try to rally world leaders to end energy dependence on Mr Putin's gas as he turns the taps off on the Nord Stream 2 pipeline.

----------

Truss has conceded that negotiations for a post-Brexit free trade deal with the US will not restart for years as she flew to New York ahead of a meeting with Joe Biden. The UK prime minister stressed her trade priority is striking agreements with India and the Gulf states, and joining a trade pact with nations including Australia and Japan. But she heavily downplayed the chances of talks even resuming to get the comprehensive deal with the States that was billed by Brexit backers as a major benefit of leaving the EU during the referendum.

----------

BROKER RATING CHANGES

----------

HSBC cuts Ocado to 'reduce' from 'hold'

----------

Credit Suisse raises Pennon to 'neutral' from 'underperform'

----------

JPMorgan places SSE on 'positive catalyst watch'

----------

COMPANIES - FTSE 100

----------

Consumer healthcare firm Haleon, in its first earnings report since being split from GSK and separately listed, reported a strong performance in the first half of 2022, noting double-digit revenue growth during the period. In the first half it reported a pretax profit of GBP864 million and revenue of GBP5.18 billion. The previous year, pretax profit totalled GBP736 million on revenue of GBP4.58 billion. Whilst noting current macro-economic challenges and uncertainties, Haleon said the positive momentum seen in the first half has continued into the second half of the year. Haleon said it is confident it is well positioned to deliver on guidance this year. Full-year revenue growth is expected between 6% and 8%.

----------

Pharmaceutical firm AstraZeneca said Evusheld, a Covid-19 treatment, has been approved in the EU for the treatments of adults and children aged 12 and over who do not require supplemental oxygen. The approval was based on results from the Tackle Phase III Covid-19 treatment trial which showed Evusheld provided clinically and statistically significant protection against progression to severe Covid-19 death against a placebo.

----------

DIY retailer Kingfisher said it delivered a first-half performance in line with expectations, while facing strong comparatives from the prior year as well as a more challenging environment. Sales in the six months that ended July 31 totalled GBP6.81 billion, down 4.1% from GBP7.10 million a year previous. Pretax profit totalled GBP474 million, down 30% against GBP677 million. Kingfisher said it had seen an "encouraging" start to trading in the second half of the year.

----------

COMPANIES - FTSE 250

----------

Online greeting card and gifting platform Moonpig said its overall trading performance from May was been in line with expectations. As a result, the firm reiterated its full-year guidance. It explained it has prioritised card sales, which have a "demonstrable track record" of resilience. Moonpig said average order values in the period have increased year-on-year and margins have remained "resilient in the absence of any significant pressure from input cost inflation".

----------

Iron ore producer Ferrexpo said has received a negative judgement from an appeal court in Ukraine regarding a claim made to invalidate a share purchase agreement from 2002 in respect of a 40% stake in Ferrexpo Poltava Mining. The court has ruled the agreement is invalid and thus the stake in Ferrexpo Poltava Mining will be transferred to the unnamed claimants. Ferrexpo said it has "compelling arguments" to defend its position.

----------

OTHER COMPANIES

----------

Healthcare software firm Craneware more than doubled its revenue in the year ended June 30. Revenue rose to USD165.5 million from USD75.6 million in the previous year. Pretax profit remained broadly flat at USD13.1 million, compared to USD13.2 million, due to amortisation of acquired intangibles and bank interest payments from the Sentry Data Systems acquisition. The firm proposed a final dividend of 15.5 pence per share, unchanged from the previous year, taking its full-year payout to 28p, up from 27.5p. Looking ahead, Craneware said it expects continued sales momentum across the group.

----------

Software developer Alfa Financial Software increased its expectations for the full-year thanks to improved contractual certainty and strong trading since its half-year results announcement at the start of September. Alfa explained it achieved improved contractual certainty with two clients, as well as request for additional people on other projects. In addition, it noted that its performance in August was "very strong" with chargeable days at a "record level".

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.